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SnapShot: Fanconi Anemia and  
Associated Proteins
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Fanconi anemia (FA) is a genetic disorder of chromosomal instability caused by mutations in at least 17 different genes (FANCA to FANCS). Patients with mutations in one 
of the FANC genes constitute a complementation group (FA-A to FA-S) (reviewed in Kottemann and Smogorzewska, 2013; Sawyer et al., 2014; LOVD database: http://www.
rockefeller.edu/fanconi/mutate/). A minority of patients are not assigned to any complementation group, and their causative mutations still await identification. FA is inherited in 
an autosomal-recessive fashion with the exception of the FA-B complementation group with mutations in FANCB, which is an X-linked gene. Clinically, FA is a heterogeneous 
disease. Patients may display diverse congenital abnormalities, including growth restriction, skeletal, and other organ malformations (reviewed in Auerbach, 2009). Most FA 
patients develop bone marrow failure (at a median age of 7 years) that may affect any of the blood lineages. However, patients with mutations in FANCO/RAD51C or FANCS/
BRCA1 show no development of bone marrow failure to date and are therefore termed to have FA-like syndrome. FA patients are cancer prone. Patients with biallelic mutations 
in FANCD1 (BRCA2) and FANCN (PALB2) develop acute myelogenous leukemia (AML) and embryonal tumors (medulloblastoma, neuroblastoma, and Wilms tumors), usually in 
the first few years of life. Patients in other complementation groups have a greatly increased risk of AML and squamous cell carcinoma, especially of the head, neck, and genital 
regions. Cells derived from FA patients show increased genomic instability and cellular hypersensitivity to DNA crosslinking agents, a characteristic that has also been used as 
a diagnostic marker for FA (reviewed in Auerbach, 2009).
The proteins encoded by the 17 genes identified to be mutated in FA patients (colored in the schematic) are implicated in a common pathway important for the repair of DNA 
interstrand crosslink (ICL) lesions that covalently link two strands of DNA together (reviewed in Deans and West, 2011; Kim and D’Andrea, 2012; Kottemann and Smogorzewska, 
2013). The pathway also involves other associated proteins (gray in the schematic) that have not yet been shown to be mutated in FA patients. ICL lesions may be formed by 
endogenous metabolites, such as reactive aldehydes (from alcohol detoxification, histone demethylation, or lipid peroxidation) or exogenous chemotherapeutic drugs, including 
cisplatin (reviewed in Clauson et al., 2013; Garaycoechea and Patel, 2014). This pathway is activated following replication fork stalling at an ICL during S phase, with the FA core 
complex (FANCA, B, C, E, F, G, L, and M) recruited through multiple mechanisms. Components of the core complex (including FANCM) have additional functions in activating 
ATR, the DNA damage response kinase, which phosphorylates multiple substrates to facilitate cell-cycle arrest, replication fork stability, and proper repair.
Once the core complex is recruited to the ICL-induced stalled replication fork, FANCL, the catalytic E3 ligase subunit of the core complex, in concert with UBE2T (ubiquitin-
conjugating enzyme), ubiqiuitinates the FANCD2-FANCI (ID2) complex. Patient cell lines with mutations in the genes coding for the core complex components show lack of 
FANCD2 or FANCI ubiquitination following DNA interstrand crosslink-inducing agents like DEB or mitomycin C (MMC). The ubiquitinated ID2 complex is essential for downstream 
nucleolytic incisions and translesion synthesis repair events. The deubiquitinating enzyme, USP1, is required to deubiquitinate the ID2 complex, and this event has been shown 
to be important for ICL repair. Two of the FA proteins, FANCP/SLX4 and FANCQ/XPF, form a complex in which the endonuclease XPF makes incisions to “unhook” the ICL. Other 
nucleases, including FAN1 (FANCD2/FANCI-associated nuclease), MUS81, and SLX1 might act redundantly to make incisions at the ICL (reviewed in Zhang and Walter, 2014). 
Unhooking allows for translesion polymerases to repair one duplex, which can then be used for repair of the other strand using homologous recombination. The remaining FA 
proteins, FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/RAD51C, and FANCS/BRCA1, are all implicated in homologous recombination repair that acts following the 
unhooking step to resolve resulting double strand breaks. In addition, FANCS/BRCA1 has been most recently implicated in unloading the replicative CMG helicase at stalled 
replication forks (Long et al., 2014).
All components of the FA pathways are conserved in vertebrates, including frogs and zebrafish. In invertebrates, such as flies and worms, FANCL is the only conserved com-
ponent of the core complex, whereas the ID2 complex and the rest of the other FA components linked to other repair pathways are present. It remains debatable whether the FA 
pathway is conserved in lower eukaryotes, including budding yeast and fission yeast as the ID2 complex, the pivotal component of the FA pathway, is not conserved. However, 
it has been suggested that the orthologs of the most conserved components, FANCM, FAAP10/FAAP16, FANCJ, FANCP, and FANCQ, operate during ICL repair in yeast when 
the predominant repair pathways are inactivated (McHugh et al., 2012).
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